Eisbach Bio GmbH’s Post

There is a growing interest in circular RNAs (circRNAs), since their discovery two decades ago. They appear to play a role in a variety of functions in normal and cancerous cells. circRNAs are formed by back-splicing of precursor mRNAs in the nucleus, then translocated to the nucleus. The mechanism for this translocation is unknown. Here, the authors show that circRNAs export pathway is independent of the pathways that regulate nuclear export of linear mRNAs texpected since they are not capped). Moreover, the authors found that Exportin-2, IGF2BP1 and Ran-GTP export circRNAs. The authors conclude that "Modulation of circRNA export pathways may have potential clinical implications as demonstrated for exportin-5 and pre-miRNA export in cancer". #cancer #oncology #rna #translocation #nucleus #cytoplasm https://lnkd.in/eGKUKSSJ

Which mechanisms regulate #immunogenic #cancer cell death via the high mobility group box 1 and 2 (#HMGB1 and #HMGB2) proteins? With help from a LUNA-FL Dual #Fluorescence #CellCounter, scientists showed the key role of the nuclear exporter #XPO1 in this process. https://ow.ly/64If50TJ6l2 #cellcount #cellcounting #oncology #oxaliplatin #calreticulin #ferroptosis

Our work has been published in Molecular Cell! 🎉 Delving into the nuanced role of PKM2 in aggressive cancer, our latest study uncovers its nuclear RNA binding properties. #Research #Science #CancerStudy #RNA

Scientists from Yale University have developed a stealthy cancer therapy: antinuclear antibody–drug conjugates (ANADCs)! ANA nuclear penetration induces nuclear flux by the lysosomal protease cathepsin B and leverage this mechanism to design an ANADC with cathepsin B-labile drug linker. The ANADC targets nucleic acid exhaust from necrotic tumors and crosses membrane barriers through nucleoside salvage as a DNA-seeking and tumor agnostic “antinuclear missile” cancer therapy. Read the full paper at ACS Publications: https://lnkd.in/e24XDMRG Study by Fei Cao et al. #Biointron #Antibodies #DrugDevelopment #DrugDiscovery #Cancer #Oncology #Innovation #ADC #Therapy #Healthcare #AntibodyEngineering

Sanford researchers Dr. Jianning Tao, Dr. Kyle Roux, Leetoria Hinojosa, Danielle May, with former graduate student Dr. Haydee Torres and undergraduate SPUR student Paige Bosshardt published an article in the Journal of Biological Chemistry investigating the nuclear interaction landscape of the oncoprotein NOTCH1.  Using a BioID approach, results identified a large set of proteins that associate with NOTCH1 and validated interactions with transcriptional repressors HDAC1 and GATAD2B in cancer cell lines.  “Comprehensive analysis of the proximity-dependent nuclear interactome for the oncoprotein NOTCH1 in live cells.”  https://lnkd.in/gn-UhRY9

What is Fight Cancer – Isotope Production Systems (IPS) program and how far does this solution innovate for the benefit of Society and Sustainability? Nuclear medicine plays a crucial role in modern healthcare with innovative treatments to fight cancer. The very low radiation of special short living isotopes is used to destroy targeted cancer cells without harming surrounding healthy tissue. One of these special isotopes applied is Luthethium-177 (Lu-177), which is already in successful commercial use to treat prostate cancer and prospect to win the fight against other cancers as well. With worldwide 18 million new cancer cases per year, and seeing the promising development and positive effects of nuclear medicine treatments, the future demand for special short living isotopes will require highly reliable and highly productive supply chains. with its parners Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), Framatome designed and commissioned the world first Isotope Production System (IPS) in an operating commercial Nuclear Power Reactor. The system can produce 200,000 patient doses of Lu-177 per year. Framatome innovative solution meets the need of high volume and reliable supply of Lu-177 to fight cancer more efficiently. Learn more: https://lnkd.in/ewrc9JdM #NuclearEnergy #HealthCare #RadioTherapy #Framatome #WNE2023 #Innovation #Framatome

What is Fight Cancer – Isotope Production Systems (IPS) program and how far does this solution innovate for the benefit of Society and Sustainability? Nuclear medicine plays a crucial role in modern healthcare with innovative treatments to fight cancer. The very low radiation of special short living isotopes is used to destroy targeted cancer cells without harming surrounding healthy tissue. One of these special isotopes applied is Luthethium-177 (Lu-177), which is already in successful commercial use to treat prostate cancer and prospect to win the fight against other cancers as well. With worldwide 18 million new cancer cases per year, and seeing the promising development and positive effects of nuclear medicine treatments, the future demand for special short living isotopes will require highly reliable and highly productive supply chains. with its parners Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), Framatome designed and commissioned the world first Isotope Production System (IPS) in an operating commercial Nuclear Power Reactor. The system can produce 200,000 patient doses of Lu-177 per year. Framatome innovative solution meets the need of high volume and reliable supply of Lu-177 to fight cancer more efficiently. Learn more: https://lnkd.in/eVttdyyP #NuclearEnergy #HealthCare #RadioTherapy #Framatome #WNE2023 #Innovation #Framatome

Nuclear #NME1 enhances the malignant behavior of A549 cells and impacts lung adenocarcinoma patient prognosis:- • NME1 is a metastatic suppressor inconsistently reported to have multiple roles as both a promoter and inhibitor of cancer metastasis. •Nevertheless, the specific mechanism behind these results is still unclear.We observed that A549 cells with stable transfer of NME1 into the nucleus (A549-nNm23-H1) exhibited significantly increased migration and invasion activity compared to vector control cells, which was further enhanced by over-expressing CYP24A1 (P<0.001). •NME1 demonstrated the ability to safely attach to and amplify the transcription activation of JUN, consequently leading to the up-regulation of CYP24A1. •Analysis of clinical data showed a positive relationship between nuclear NME1 levels and CYP24A1 expression. Furthermore, they were positively associated with postoperative distant metastasis and negatively correlated with prognosis in those with early-stage lung adenocarcinoma. •In conclusion, the data presented provides a new understanding of the probable pathways by which nuclear NME1 facilitates tumor metastasis, establishing the groundwork for future prediction and treatment of tumor metastasis. #highlights:- •NME1 is both a promoter and inhibitor of cancer metastasis. •The dual role of NME1 in tumors is related to nuclear and cytoplasmic localization. •Nuclear NME1 up-regulates CYP24A1 expression in A549 cells. •The binding of NME1 and JUN promotes the transcriptional activity of JUN.

What is Fight Cancer – Isotope Production Systems (IPS) program and how far does this solution innovate for the benefit of Society and Sustainability? Nuclear medicine plays a crucial role in modern healthcare with innovative treatments to fight cancer. The very low radiation of special short living isotopes is used to destroy targeted cancer cells without harming surrounding healthy tissue. One of these special isotopes applied is Luthethium-177 (Lu-177), which is already in successful commercial use to treat prostate cancer and prospect to win the fight against other cancers as well. With worldwide 18 million new cancer cases per year, and seeing the promising development and positive effects of nuclear medicine treatments, the future demand for special short living isotopes will require highly reliable and highly productive supply chains. with its parners Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), Framatome designed and commissioned the world first Isotope Production System (IPS) in an operating commercial Nuclear Power Reactor. The system can produce 200,000 patient doses of Lu-177 per year. Framatome innovative solution meets the need of high volume and reliable supply of Lu-177 to fight cancer more efficiently. Learn more: https://lnkd.in/d6rRy8BG #NuclearEnergy #HealthCare #RadioTherapy #Framatome #WNE2023 #Innovation #Framatome

Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine DPI-4452 is a potential theranostic ligand for carbonic anhydrase IX (CAIX), a protein highly expressed in certain tumor types. The ligand was evaluated in vitro and in vivo using radiolabeled versions and showed selective binding to CAIX with high affinity. In animal models, the ligand localized to tumors and demonstrated tumor growth inhibition. This suggests that DPI-4452 could be used for selecting and treating patients with CAIX-expressing tumors.